DeepMind’s AI Predicts Structures for More Than 350,000 Proteins
In 2003, researchers sequenced approximately 92% of the human genome, a huge achievement and very recently researchers have completed the entire process. Now, the latest innovation in AI technology has predicted the structure of nearly the entire human proteome. The...
3 years agoDeepMind’s AI Predicts Structures for More Than 350,000 Proteins
In 2003, researchers sequenced approximately 92% of the human genome, a huge achievement and very recently researchers have completed the entire process. Now, the latest innovation in AI technology has predicted the structure of nearly the entire human proteome. The...
3 years agoCOVID-19 Booster Controversy: Disputes Across the Pharma Industry
Despite almost two thirds of the adult population in the UK having been vaccinated, cases are on the rise, which appear to be associated with the highly-transmissible delta variant of COVID-19. According to The European Centre for Disease Prevention and Control,...
3 years agoCOVID-19 Booster Controversy: Disputes Across the Pharma Industry
Despite almost two thirds of the adult population in the UK having been vaccinated, cases are on the rise, which appear to be associated with the highly-transmissible delta variant of COVID-19. According to The European Centre for Disease Prevention and Control,...
3 years agoCOVID’s Impact on Innovations in Regulatory Affairs
While the impact of COVID-19 was significant in every area of the pharmaceutical sector, some of the most pandemic’s most overlooked impacts were within the regulatory space. From study design to submissions, the virus affected every aspect of drug regulation,...
3 years agoCOVID’s Impact on Innovations in Regulatory Affairs
While the impact of COVID-19 was significant in every area of the pharmaceutical sector, some of the most pandemic’s most overlooked impacts were within the regulatory space. From study design to submissions, the virus affected every aspect of drug regulation,...
3 years agoThe Latest Advancements in Immuno-oncology: Checkpoint Inhibitors
Until now, patients with advanced cervical cancer had relatively low survival rates. The recent approval of Keytruda, a PD-1/PD-L1 checkpoint inhibitor, is the latest breakthrough for cervical cancer immunotherapy. The positive outcome from Merck & Co’s clinical trial now offers...
4 years agoThe Latest Advancements in Immuno-oncology: Checkpoint Inhibitors
Until now, patients with advanced cervical cancer had relatively low survival rates. The recent approval of Keytruda, a PD-1/PD-L1 checkpoint inhibitor, is the latest breakthrough for cervical cancer immunotherapy. The positive outcome from Merck & Co’s clinical trial now offers...
4 years agoBuilding a FAIR Culture in Pharma
The development of a ‘Findable, Accessible, Interoperable and Reusable’ (FAIR) data approach has been an exciting step towards an information-centric approach for the pharmaceutical industry. The potential benefits of this alternative approach to data management and accessibility could significantly support...
4 years agoBuilding a FAIR Culture in Pharma
The development of a ‘Findable, Accessible, Interoperable and Reusable’ (FAIR) data approach has been an exciting step towards an information-centric approach for the pharmaceutical industry. The potential benefits of this alternative approach to data management and accessibility could significantly support...
4 years agoUtilising Machine Learning in Drug Discovery: Opportunities and Challenges
From artificial neural networks to predictive modelling, artificial intelligence (AI) is making its mark in the pharmaceutical industry. The ever-increasing cost of development, shorter timelines and rise in demand has seen the industry reach out to AI to help bring...
4 years agoUtilising Machine Learning in Drug Discovery: Opportunities and Challenges
From artificial neural networks to predictive modelling, artificial intelligence (AI) is making its mark in the pharmaceutical industry. The ever-increasing cost of development, shorter timelines and rise in demand has seen the industry reach out to AI to help bring...
4 years agoEmisphere’s Stockholders Sue Over Novo Nordisk Purchase
For daily articles on the latest pharma trends and innovations, as well as interviews with leading experts and in-depth industry White Papers, subscribe to PharmaFeatures.com. A trio of lawsuits are being levelled at Emisphere Technologies over its recent sale to Novo...
4 years agoEmisphere’s Stockholders Sue Over Novo Nordisk Purchase
For daily articles on the latest pharma trends and innovations, as well as interviews with leading experts and in-depth industry White Papers, subscribe to PharmaFeatures.com. A trio of lawsuits are being levelled at Emisphere Technologies over its recent sale to Novo...
4 years agoThe Potential of Therapeutic Psychedelics Drugs: An Interview with Professor Albert Garcia-Romeu
Mental health conditions like addiction and diseases like Alzheimer’s represent a great unmet clinical need. Psychedelic research at preclinical stages have shown potential for positive neurological changes in the brain for models of depression, addiction and Alzheimer's. In a recent...
4 years agoThe Potential of Therapeutic Psychedelics Drugs: An Interview with Professor Albert Garcia-Romeu
Mental health conditions like addiction and diseases like Alzheimer’s represent a great unmet clinical need. Psychedelic research at preclinical stages have shown potential for positive neurological changes in the brain for models of depression, addiction and Alzheimer's. In a recent...
4 years agoLatest Advancements in Parkinson’s Treatment: CGT Shows Potential to Reverse Disease
Every hour, two more people are diagnosed with Parkinson’s in the UK and the global patient population continues to rise. To date, there are no disease-modifying therapies available on the market for Parkinson's (PD) patients. Pharmaceutical company Bayer is simultaneously...
4 years agoLatest Advancements in Parkinson’s Treatment: CGT Shows Potential to Reverse Disease
Every hour, two more people are diagnosed with Parkinson’s in the UK and the global patient population continues to rise. To date, there are no disease-modifying therapies available on the market for Parkinson's (PD) patients. Pharmaceutical company Bayer is simultaneously...
4 years agoVaccines and Variants: How Do They Work?
As of 23 June 2021, there are 14 variants of COVID-19 which are of concern or under investigation in the UK, according to the UK government. The unique profile of COVID-19 enables rapid mutation, producing variants which are more transmissible...
4 years agoVaccines and Variants: How Do They Work?
As of 23 June 2021, there are 14 variants of COVID-19 which are of concern or under investigation in the UK, according to the UK government. The unique profile of COVID-19 enables rapid mutation, producing variants which are more transmissible...
4 years ago